Axovia Therapeutics Presents New Preclinical Data for AXV-101 for the Treatment of Blindness Associated with BBS Mutations at ASGCT

Contributed by: GlobeNewswire

Tags

GENE THERAPY

More Like This

Axovia Therapeutics Announces Presentation of Preclinical Data Supporting Lead Program AXV-101 for Treatment of Blindness Associated with BBS1 Mutations at ASGCT

Axovia Therapeutics Announces Three Upcoming Poster Presentations at ASGCT

ALSA Ventures launches novel Gene Therapy portfolio company Axovia Therapeutics to treat Ciliopathies

A Race Against Blindness Grants $1 Million Supporting Axovia Therapeutics’ Planned Clinical Trial for Bardet-Biedl Syndrome (BBS)

A Race Against Blindness Announces $2 Million Grant to Support Sight-Saving Clinical Trial

AviadoBio Announces Presentation of Promising Preclinical Safety and Biodistribution Data of its Gene Therapy Candidate AVB-101 for FTD-GRN at the Annual European Society of Gene and Cell Therapy Congress

PR Newswire associated0

HUIDAGENE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN MULTINATIONAL PHASE 1/2 TRIAL OF HG004 FOR INHERITED BLINDNESS

AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN